Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases.

Abstract

QoL provides a better survival estimate than measurement of tumor size and could be used as a surrogate end point for survival in treatment trials.

Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models

“…Rather, it is fully in line with the already consolidated evidence found in a number of other cancer populations [19]. Several studies have in fact shown that self-reported QoL frequently replaces important clinical data, such as performance status or tumor size, in final multivariate prognostic models [20,21].…”

Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer

“…One explanation for the deterioration in the quality of life (QoL) of colorectal cancer patients (Earlam et al, 1996) is an immune response to tumour-related products. In support of this, QoL impairment in colorectal liver metastasis (CLM) patients has been shown to correlate more closely with extent of immune activation than with liver metastasis volume or the serum level of the tumour marker carcinoembryonic antigen (CEA) (Allen-Mersh et al, 1998).…”

Quality of life and survival prediction in terminal cancer patients

“…[1][2][3][4] More specifically, studies have suggested that such an association may exist among patients with advanced malignancies of the breast, 4 -10 esophagus, 11 colorectum, 2,12 skin (melanoma), 13,14 and lung. 2,[15][16][17][18][19][20] This trend also may occur among patients with terminal cancer 21 ; however, the magnitude and clinical relevance of these effects remain unclear.…”